- Home
- JANX vs OI Comparison
JANX vs OI Comparison
Compare JANX & OI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- OI
- Stock Information
- Founded
- JANX 2017
- OI 1903
- Country
- JANX United States
- OI United States
- Employees
- JANX N/A
- OI N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- OI Containers/Packaging
- Sector
- JANX Health Care
- OI Consumer Discretionary
- Exchange
- JANX Nasdaq
- OI Nasdaq
- Market Cap
- JANX 1.6B
- OI 1.8B
- IPO Year
- JANX 2021
- OI N/A
- Fundamental
- Price
- JANX $26.37
- OI $13.09
- Analyst Decision
- JANX Strong Buy
- OI Buy
- Analyst Count
- JANX 7
- OI 8
- Target Price
- JANX $94.29
- OI $15.50
- AVG Volume (30 Days)
- JANX 974.6K
- OI 1.4M
- Earning Date
- JANX 05-20-2025
- OI 04-29-2025
- Dividend Yield
- JANX N/A
- OI N/A
- EPS Growth
- JANX N/A
- OI N/A
- EPS
- JANX N/A
- OI N/A
- Revenue
- JANX $10,588,000.00
- OI $6,505,000,000.00
- Revenue This Year
- JANX N/A
- OI $1.19
- Revenue Next Year
- JANX $250.58
- OI $1.15
- P/E Ratio
- JANX N/A
- OI N/A
- Revenue Growth
- JANX 30.99
- OI N/A
- 52 Week Low
- JANX $22.52
- OI $9.23
- 52 Week High
- JANX $71.71
- OI $15.72
- Technical
- Relative Strength Index (RSI)
- JANX 39.10
- OI 66.20
- Support Level
- JANX $31.34
- OI $12.80
- Resistance Level
- JANX $33.97
- OI $13.49
- Average True Range (ATR)
- JANX 1.94
- OI 0.47
- MACD
- JANX -0.52
- OI 0.17
- Stochastic Oscillator
- JANX 22.76
- OI 85.66
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.